Ethical and Economic Issues in the Appraisal of Medicines for Ultra-Rare Conditions

Nadine Henderson;Maria Errea;Chris Skedgel;Mireia Jofre-Bonet

Contract Research from Office of Health Economics

Abstract: In light of concerns that not all medicines for ultra-rare (also known as ultra-orphan) conditions are appraised under the same NICE process, a new OHE Consulting Report discusses the distinct ethical and economic challenges faced by medicines for ultra-rare conditions, with particular reference to the challenges of HTA in the UK. A failure to consistently consider all ultra-rare disease medicines under the HST process could lead to inequalities in access and health outcomes for patients with ultra-rare conditions.

Keywords: Ethical; and; Economic; Issues; in; the; Appraisal; of; Medicines; for; Ultra-Rare; Conditions (search for similar items in EconPapers)
JEL-codes: I1 (search for similar items in EconPapers)
Date: 2020-01-01
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.ohe.org/publications/ethical-and-econo ... ic-challenges-final/ (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:ohe:conres:002236

Access Statistics for this paper

More papers in Contract Research from Office of Health Economics Contact information at EDIRC.
Bibliographic data for series maintained by Publications Manager ( this e-mail address is bad, please contact ).